基本情報
- CAS
81403-68-1- 標準SMILES
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl- InChIKey
YTNKWDJILNVLGX-UHFFFAOYSA-N- 分子式
- C19H28ClN5O4
- 平均分子量
- 425.9 g/mol
- 単同位体質量
- 425.1829821
概要
Alfuzosin Hydrochloride is the hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance.
名称と識別子
- 優先名称
- Alfuzosin Hydrochloride
- IUPAC
- N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
- 現地名
- アルフゾシン·塩酸塩
- 英語名
- Alfuzosin hydrochloride
- 分子式
- C19H28ClN5O4
- 分子量
- 425.91
名称と別名
Alfuzosin Hydrochloride81403-68-1Alfuzosin HClXatralXatral SRSL 77 499-10DTXSID3045514Alfutral srBenestan retBesavar xlFuzatal xlKelanu xl
名称をさらに表示
アルフゾシン·塩酸塩アルフゾシン塩酸塩4-アミノ-6,7-ジメトキシ-2-[メチル[3-[(テトラヒドロ-2-フロイル)アミノ]プロピル]アミノ]キナゾリン塩酸塩N-[3-[(4-アミノ-6,7-ジメトキシ-2-キナゾリニル)(メチル)アミノ]プロピル]テトラヒドロ-2-フランカルボキサミド塩酸塩アルフゾシン 塩酸塩アルフゾシン塩酸塩 (JAN)塩酸アルフゾシンアルフゾシン・塩酸塩URIONAlfotenMITTOVALUroxatralUROXANTRALUdon：xatralSL-77,499-10Alfuzosin-d7 HCl
Vasran xlN-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide hydrochloride75046A1XTNSL-77499-10SL 77499-10DTXCID1025514SL-77-499-10CHEBI:32286
データベース識別子
- CAS
物性
構造計算による物性
- 極性表面積
- 112 Ų
- 水素結合供与体数
- 3
- 水素結合受容体数
- 8
- 回転可能結合数
- 8
- 重原子数
- 29
- 形式電荷
- 0
- 複雑度
- 511
実験および物理化学的性質
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
物理化学的性質
- 融点
- 225 °C · 225°C
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 10 mg/mL · DMSO：>10mg/mL
- 酸解離定数(Pka)
- 8.13 · 8.13(at 25℃)
- 外見
- 個体
- 色
- ホワイトからオフホワイト
- Merck
- 14 · 14,238
- InChI
- InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
- InChIKey
- YTNKWDJILNVLGX-UHFFFAOYSA-N
- SMILES
- C12=C(N)N=C(N(C)CCCNC(=O)C3OCCC3)N=C1C=C(OC)C(OC)=C2.Cl
- CAS データベース
- 81403 · 81403-68-1(CAS DataBase Reference)
化学的性質
化学的特性White to Off-White Solid
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (93.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 73 reports by companies from 6 notifications to the ECHA C&L Inventory.
危険有害性情報
Hazard Classes and CategoriesAcute Tox. 4 (93.2%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Alfuzosin hydrochloride
vLess-DILI-concern
5
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
安全データ
- wgk
- 3
- rtecs
- LT9965475
- hs_code
- 2934990002
- risk_code
- 22
- hazard_code
- Xn
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
FDA Pharmacological Classification
ALFUZOSIN HCL
alpha-Adrenergic Blocker [EPC]; Adrenergic alpha-Antagonists [MoA]
ALFUZOSIN HYDROCHLORIDE
alpha-Adrenergic Blocker [EPC]; Adrenergic alpha-Antagonists [MoA]
MeSH Pharmacological Classification
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.
応用分野
説明Alfuzosin (SL-77499) (I), a quinazoline derivative which is a uroselective alpha-1 adrenoreceptor antagonist, has been developed and launched worldwide by Sanofi-Synthelabo, for the treatment of benign prostate hyperplasia (BPH). In November 2003, alfuzosin (I) was launched as an extended release formulation in the US as Uroxatral utilizing Skyepharma’s oral controlled release technology.
使用α1-Adrenoceptor antagonist structurally similar to Prozosin. Antihypertensive. Alfuzosin hydrochloride is used in treatment of benign prostatic hypertrophy.
一般的な説明Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
上流・下流製品情報
上流原料
関連反応
1 件
化合物ノート
読み込み中…